Ubiquinone (Coenzyme Q10) and mitochondria in oxidative stress of parkinson’s disease

NeuroSignals

Volumn 10, Issue 3-4, 2001, Pages 224-253

  Ebadi, M ^a   Govitrapong, P ^a   Sharma, S ^a   Muralikrishnan, D ^a   Shavali, S ^a   Pellett, L ^a   Schafer, R ^a   Albano, C ^a   Eken, Josh ^a  

^a UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Apoptosis; Complex I; Dopaminergic neurons; Mitochondria; Parkinson rsquo; s disease; Ubiquinol; Ubiquinone

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; COPPER DERIVATIVE; CYTOCHROME C OXIDASE; FLAVINE ADENINE NUCLEOTIDE; FLAVINE MONONUCLEOTIDE; HEME; IRON DERIVATIVE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SUCCINATE DEHYDROGENASE (UBIQUINONE); SULFUR DERIVATIVE; UBIDECARENONE; UBIQUINOL CYTOCHROME C REDUCTASE; OXIDOREDUCTASE; UBIQUINONE;

ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX; CHROMOSOME 4; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; ENZYME ACTIVITY; ENZYME INHIBITION; GLOBUS PALLIDUS; HUMAN; LEWY BODY; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PARKINSON DISEASE; POINT MUTATION; SUBSTANTIA NIGRA; AGING; CORPUS STRIATUM; DNA DAMAGE; METABOLISM; PHYSIOLOGY; REVIEW;

AGING; CORPUS STRIATUM; DNA DAMAGE; ELECTRON TRANSPORT COMPLEX I; HUMANS; MITOCHONDRIA; NADH, NADPH OXIDOREDUCTASES; OXIDATIVE STRESS; PARKINSON DISEASE; SUBSTANTIA NIGRA; UBIQUINONE;

EID: 0034744308     PISSN: 1424862X     EISSN: 14248638     Source Type: Journal    
DOI: 10.1159/000046889     Document Type: Article

References (129)

1. Wilson JX: Antioxidant defense of the brain: A role for astrocytes. Can J Physiol Pharmacol 1997;75:1149-1163.
2. Palmer HJ, Paulson KE: Reactive oxygen species and antioxidants in signal transduction and gene expression. Nutr Rev 1997;55:353-361.
3. Sun Y, Oberly LW: Redox regulation of transcriptional activators. Free Radic Biol Med 1996;21:335-348.
4. Winyard PO, Blake DR: Antioxidants, redox-regulated transcription factors, and inflammation. Adv Pharmacol 1997;38:403-421.
5. Powis G, Gasdaska JR, Baker A: Redox signaling and the control of cell growth and death. Adv Pharmacol 1997;38:329-359.
6. Walker LJ, Robson CN, Black E: Identification of residues in the human DNA repair enzyme HAP1 (ref-1) that are essential for redox regulation of jun DNA binding. Mol Cell Biol 1993;13:5370-5376.
7. Hayashi T, Ueno Y, Okamoto T: Oxidoreductive regulation of nuclear factor kB: Involvement of a cellular reducing catalyst thioredox-in. J Biol Chem 1993;268:11380-11388.
8. Xanthoudakis S, Curran T: Redox regulation of AP-1: A link between transcription factor signaling and DNA repair. Adv Exp Biol Med 1996;387:69-75.
9. Knoepfel L, Steinkuhler C, Carri MT, Rotilio G: Role of zinc-coordination and of the glutathione redox couple in the redox susceptibility of human transcription factor Sp1. Biochem Biophys Res Commun 1994;201:871-877.
10. Wu X, Bishopric NH, Discher DJ: Physical and functional sensitivity of zinc finger transcription factors to redox change. Mol Cell Biol 1996; 16:1035-1046.
11. Shoffner JM, Wallace DC: Oxidative phosphorylation diseases. Disorder of two genomes. Adv Hum Genet 1990;19:267-330.
12. Babior BM, Crowley CA: Chronic granulomatous disease and other disorders of oxidative killing by pha-goeytes; in Stanbury JB, Wyngaard-en JB, Fredrickson DS, Goldstein JL, Brown MS (eds): The Metabolic Basis of Inherited Disease, ed 5. New York, McGraw-Hill Book, 1983, pp 1986-1994.
13. Shoffner JM, Wallace DC: Oxidative phosphorylation diseases and mitochondrial DNA mutations: Diagnosis and treatment. Annu Rev Nutr 1994;14:535-568.
14. Wallace DC: Mitochondrial DNA in aging and disease. Sci Am 1997;277: 40-47.
15. Klingenberg M: The ADP-ATP translocation in mitochondria, a membrane potential controlled transport. J Membr Biol 1980;56: 97-105.
16. Miyoshi H: Structure-activity relationships of some complex I inhibitors. Biochim Biophys Acta 1998; 1364:236-244.
17. Schapira AHV, Cooper JM, Dexter D: Mitochondrial complex I deficiency in Parkinson’s disease. Lancet 19891: 1269.
18. Schapira AHV, Mann VM, Hartley A, Cooper JM, Daniel SE, Marsden CD: Complex I deficiency in Parkinson’s disease. Mov Disord 1993; 8:403-404.
19. Parker WD Jr, Boyson SJ, Park JK: Abnormalities of the electron transport chain in idiopathic Parkinson’s disease. Ann Neurol 1989;26:719-723.
20. Bindoff LA, Birch-Machin M, Cart-lidge NEF, Parker WD Jr, Turnbull DM: Mitochondrial function in Parkinson’s disease. Lancet 1989;ii:49.
21. Krige D, Carroll MT, Cooper JM, Marsden CD, Schapira AHV: Platelet mitochondrial function in Parkinson’s disease. Ann Neurol 1992; 32:782-788.
22. DiMonte DA, Sandy MS, Jewell SA, Adomato B, Tanner CM, Langston JW: Oxidative phosphorylation by intact muscle mitochondria in Parkinson’s disease. Neurodegeneration 1993;2:275-328.
23. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ: A primate model of parkinsonism; selective destruction of dopaminergic neurons in the pars com-pacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine. Proc Natl Acad Sci USA 1983;80:4546-4550.
24. Glinka Y, Tipton KF, Youdim MBH: Mechanism of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine and its prevention by desferrioxamine. Eur J Pharmacol 1998;351:121-129.
25. Mayo JC, Sainz RM, Uria H, Antolin I, Esteban MM, Rodriquez C: Melatonin presents apoptosis induced by 6-hydroxydopamine in neuronal cells: Implications for Parkinson’s disease. J Pineal Res 1998; 24:179-192.
26. Kosel S, Grasbon-Frodl EM, Mautsch U, Egensperger R, von Eitzen U, Frishman D, Hofmann S, Klaus-Dieter G, Mehracin P, Grae-ber MB: Novel mutations of mitochondrial complex I in pathologically proven Parkinson disease. Neurogen 1998;1:197-204.
27. Bowling AC, Mutisya EM, Walker LC, Price DL, Cork LC, Beal MF: Age-dependent impairment of mitochondrial function in primate brain. J Neurochem 1993;60:1964-1967.
28. DiMonte DA, Sandy MS, DeLan-ney LE, Jewell SA, Chan P, Irwin I, Langston JW: Age-dependent changes in mitochondrial energy production in striatum and cerebellum of the monkey brain. Neurodegeneration 1993;2:93-99.
29. Tsujimoto Y: Apoptosis and necrosis: Intracellular ATP level as a determinant for cell death modes. Cell Death Differen 1997;4:429-434.
30. Davey GP, Peuchen S, Clark JB: Energy thresholds in brain mitochondria potential involvement in neurodegeneration. J Biol Chem 1998; 273:12753-12757.
31. 10attenuates the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res 1998;783:109-114.
32. Wallace DC: Diseases of the mitochondrial DNA. Annu Rev Biochem 1992;61:1175-1212.
33. Beal MF: Mitochondrial Dysfunction and Oxidative Damage in Neurodegenerative Disease. Austin, Landes, 1995.
34. Merrill CR, Zullo S, Ghanbari H: Possible relationship between conditions associated with chronic hypoxia and brain mitochondrial DNA deletions. Arch Biochem Biophys 1996;326:172-177.
35. Ozawa T, Tanaka M, Ikebe SI, Ohno K, Kondo T, Mizuno Y: Quantitative determination in parkinsonian striatum by a kinetic PCR analysis. Biochem Biophys Res Commun 1990;172:483-489.
36. Ikebe SI, Tanaka M, Ohno K: Increase of deleted mitochondrial DNA in striatum in Parkinson’s disease and senescence. Biochem Bio-phys Res Commun 1990;170:1044-1048.
37. Boyer PD: Energy, life, and ATP. Angew Chem Int Ed 1998;37:2296-2307.
38. Richter C: Oxidative damage to mitochondrial DNA and its relationship to aging. Int Biochem Cell Biol 1995;27:647-653.
39. Calne DB, Eisen A, McGeer E, Spencer P: Alzheimer’s disease, Parkinson’s disease, and motoneurone disease: Abiotrophic interaction between aging and environment? Lancet 1986;ii: 1067-1070.
40. Braak H, Braak E: Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991;82: 239-259.
41. Gibb WRG, Lees AJ: Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1991;54:388-396.
42. Cruz-Sanchez FF, Cardozo A, Cas-tejon C, Tolosa E, Rossi ML: Aging and the nigro-striatal pathway. J Neural Transm 1997;51:9-25.
43. Hodge CF: Changes in the ganglion cells from birth to senile death. Observations of man and honey-bee. J Physiol 1894;17:129-134.
44. McGeer PL, McGeer EG, Suzuki JS: Aging and the extrapyramidal function. Arch Neurol 1977;34:33-35.
45. Mann DMA, Yates PO, Marcyniuk B: Monoaminergic neurotransmitter systems in presenile Alzheimer’s disease and in senile dementia of Alzheimer type. Clin Neuropathol 1984;13:99-205.
46. Thiessen B, Rajput AH, Laverty W, Desai H: Age, environments and the number of substantia nigra neurons; in Streifler MB, Korczyn AD, Melamed E, Youdim MBH (eds): Parkinson’s Disease: Anatomy-Pathology, and Therapy. New York, Raven Press, 1990, pp 201-206.
47. Fearnley JM, Lees AJ: Aging and Parkinson’s disease: Substantia nigra regional selectivity. Brain 1991; 114:2283-2301.
48. Machado-Salas J, Scheibel ME, Scheibel AB: Neuronal changes in the aging mouse: Spinal cord and lower brain stem. Exp Neurol 1977; 54:504-512.
49. Cruz-Sanchez FF, Cardoza A, Tolo-sa E: Neuronal changes in the substantia nigra with aging: A Golgi study. J Neuropathol Exp Neurol 1995;54:74-81.
50. Boatell ML, Mahy N, Cardozo A, Ambrosio S, Tolosa E, Cruz-San-chez FF: Neuronal changes in the nigrostriatal pathway of 1-methyl-4-phenylpyridine-treated mice. Methods Find Exp Clin Pharmacol 1992; 14:781-787.
51. Patt S, Gertz HJ, Lieselote G, Cer-vos-Navarro J: Pathological changes in dendrites of substantia nigra neurons in Parkinson’s disease: A Golgi study. Histol Histopathol 1991;6: 373-380.
52. Delanty N, Dichter MA: Oxidative injury in the nervous system. Acta Neurol Scand 1998;98:145-153.
53. Chan PH, Chu L, Chen SF, Carlson EJ, Epstein CJ: Reduced neurotoxicity in transgenic mice overexpressing human copper-zinc-superoxide dismutase. Stroke 1990;21(suppl 3): 80-82.
54. Greenlund LJS, Deckwerth TL, Johnson EM: Superoxide dismutase delays neuronal apoptosis: A role of reactive oxygen species in programmed neuronal death. Neuron 1995; 14:303-315.
55. Stoian I, Oros A, Moldoveanu E: Apoptosis and free radicals. Bio-chem Mol Med 1996;59:93-97.
56. Palmer HJ, Paulson KE: Reactive oxygen species and antioxidants in signal transduction and gene expression. Nutr Rev 1997;55:353-361.
57. Frank L, Massaro D: Oxygen toxicity. Am J Med 1980;69:117-126.
58. Ames BN, Shigenda MK, Hagen TM: Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci USA 1993;90:7915-7922.
59. Edgington SM: As we live and breathe: Free radicals and aging. Biotechnology 1994;12:37-40.
60. Tanaka M, Gong J-S, Zhang J, Yon-eda M, Yaci K: Mitochondrial genotype associated with longevity. Lancet 1998;351:185-186.
61. Halliwell B: Free radicals, antioxidants, and human disease: Curiosity, cause, or consequence? Lancet 1994;344:721-724.
62. Hennekens CH, Buring JE, Peto R: Antioxidant vitamins benefits not yet proved. N Engl J Med 1994;330: 1080-1081.
63. Greenberg ER, Sporn MB: Antioxidant vitamins, cancer, and cardiovascular disease. N Engl J Med 1996;334:1189-1190.
64. Sofic E, Paulus W, Jellinger K, Rie-derer P, Youdim MBH: Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem 1991;56:978-982.
65. Sian J, Dexter DT, Lees AJ: Alterations in glutathione levels in Parkinson’s disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 1994;36:348-355.
66. Wei Q, Yeung M, Jurma OP, Anderson JK: Genetic elevation of monoamine oxidase levels in dopaminergic PC12 cells results in increased free radical damage and sensitivity to MPTP. J Neurosci Res 1996;46: 666-673.
67. Cohen G: The brain on fire. Ann Neurol 1994;36:333-334.
68. Nakao N, Frodl EM, Duan W-M, Widner H, Brundin P: Lazaroids improve the survival of grafted rat embryonic dopamine neurons. Proc Natl Acad Sci USA 1994;91:2408-2412.
69. Nakao N, Frodl EM, Widner H: Overexpressing Cu/Zn superoxide dismutase enhances survival of transplanted neurons in a rat model of Parkinson’s disease. Nat Med 1995;1:226-231.
70. The Parkinson’s Disease Study Group: Effects of tocopherol and deprenyl on the progression of disability early Parkinson’s disease. N Engl J Med 1993;328:176-183.
71. May JM, Qu Z-C, Mendiratta S: Protection and recycling of a-toco-pherol in human erythrocytes by intracellular ascorbic acid. Arch Bio-chem Biophys 1998;349:281-289.
72. Parker WD Jr, Boyson SJ, Parks JK: Abnormalities of the electron transport chain in idiopathic Parkinson’s disease. Ann Neurol 1989;26:719-723.
73. Kurland LT: Epidemiology: Incidence, geographic distribution and genetic considerations; in Fields W (ed): Pathogenesis and Treatment of Parkinsonism. Springfield, Thomas, 1958, pp 5-49.
74. Caine S, Schoenberg B, Martin W: Familial Parkinson’s disease. Possible role of environmental factors. Can J Neurol Sci 1987;14:303-305.
75. Langston JW, Ballard P, Tetrud JW, Irwin I: Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979-980.
76. Ramsey RR, Singer TP: Energy dependent uptake of 1-methyl-4-phe-nylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine, by mitochondria. J Biol Chem 1986;261:7585-7587.
77. Ramsay RR, Salach JI, Singer TP: Uptake of the neurotoxin 1-methyl-4-phenylpyridine (MPP+) by mitochondria and its relation to the inhibition of the mitochondrial oxidation of NAD+-linked substrates by MPP+. Biochem Biophys Res Com-mun 1986;134:743-748.
78. Nicklas WJ, Vyas I, Heikkila RE: Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrid-ine. Life Sci 1985;36:2503-2508.
79. Ramsay RR, Salach JI, Dadgar J, Singer TP: Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic parkinsonism. Biochem Biophys Res Commun 1986;135:269-275.
80. Vyas I, Heikkila RE, Nicklas WJ: Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydro-pyridine: Inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-pyridinium. J Neu-rochem 1986;46:1501-1507.
81. Kindt MV, Heikkila RE, Nicklas WJ: Mitochondrial and metabolic toxicity of 1-methyl-4-(2'-methyl-phenyl)-1,2,3,6-tetrahydropyridine. J Pharmacol Exp Ther 1987;242: 858-863.
82. Heron C, Smith S, Ragan CI: An analysis of the polypeptide composition of bovine heart mitochondrial NADH-ubiquinone oxidoreductase by two-dimensional polyacrylamide-gel electrophoresis. Biochem J 1979;181:435-443.
83. Chomyn A, Mariottini P, Cleeter MWJ: Six unidentified reading frames of human mitochondrial DNA encode components of the respiratory-chain NADH dehydrogenase. Nature 1985;314:592-597.
84. Chomyn A, Cleeter MWJ, Ragan CI: UPF6, last unidentified reading frame of human mtDNA code, for an NADH dehydrogenase subunit. Science 1986;234:614-618.
85. Parker WD, Oley CA, Parks JK: Deficient NADH:coenzyme Q oxido-reductase activity in Leber’s hereditary optic neuropathy. N Engl J Med 1989;320:1331-1333.
86. Wallace DC: A new manifestation of Leber’s disease and a new explanation for the agency responsible for its unusual pattern of inheritance. Brain 1970;93:121-132.
87. Wallace DC, Gurparkash S, Lott MT: Mitochondrial DNA mutation associated with Leber’s hereditary optic atrophy. Science 1988;242: 1427-1430.
88. Uitti RJ, Rajput AH, Ashenhurst EM, Rozdislky B: Cyanide-induced parkinsonism: A clinicopathologic report. Neurology 1985;35:921-925.
89. Krishnamoorthy G, Hinkle PC: Studies on the electron transfer pathway, topography of iron-sulfur centers, and site of coupling in NADH-Q oxidoreductase. J Biol Chem 1988;263:17566-17575.
90. Shoulson I, Fahn S, Langston W: Symposium on the etiology, pathogenesis, and prevention of Parkinson’s disease. Arch Neurol 1988;45: 807-811.
91. Jellinger KA: Cell death mechanisms in Parkinson’s disease. J Neural Transm 2000;107:1-29.
92. Boada J, Cutillas B, Roig T, Bermudez J, Ambrosio S: MPP+-induced mitochondrial dysfunction is potentiated by dopamine. Biochem Bio-phys Res Commun 2000;268:916-920.
93. Banaclocha M: A-Acetylcysteine elicited increase in complex I activity in synaptic mitochondria from aged mice: Implications for treatment of Parkinson’s disease. Brain Res 2000;859:173-175.
94. Seaton TA, Cooper JM, Schapira AHV: Free radical scavengers protect dopaminergic cell lines from apoptosis induced by complex I inhibitors. Brain Res 1997;777:110-118.
95. Aveliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho W-H, Castillo PE, Shinsky N, Verdugo JMG, Armanini M, Ryan A, Hynes M, Phillips H, Sulzer D, Rosenthal A: Mice lacking a-synuclein display functional deficits in the nigrostria-tal dopamine system. Neuron 2000; 25:239-252.
96. Masliah E, Rockenstein E, Vein-bergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L: Dopaminergic loss and inclusion body formation in a-synuclein mice: Implications for neurodegenerative disorders. Science 2000;287:1265-1269.
97. Polymeropoulos MH, Lavedan C, Leroy E: Mutation in the a-synu-clein gene identified in families with Parkinson’s disease. Science 1997; 276:2045-2047.
98. Kruger R, Kuhn W, Muller T: Ala30Pro mutation in the gene encoding a-synuclein in Parkinson’s disease. Nat Genet 1998; 18:106-108.
99. Kitada T, Asakawa S, Hattori N: Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998;392:605-608.
100. Hattori N, Matsumine H, Asaka-wa S: Point mutations (Thr240Arg and Ala311Stop) in the Parkin gene. Biochem Biophys Res Com-mun 1998;249:754-758.
101. Lucking CB, Abbas N, Durr A: Homozygous deletions in parkin gene in European and North African families with autosomal recessive juvenile parkinsonism. The European Consortium on Generic Susceptibility in Parkinson’s Disease and the French Parkinson’s Disease Genetics Study Group. Lancet 1998;352:1355-1356.
102. Mori H, Kondo T, Yokochi M: Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology 1998;51:890-892.
103. Leroy E, Boyer R, Auburger G: The ubiquitin pathway in Parkinson’s disease. Nature 1998;395: 451-452.
104. Clayton DF, George JM: The sy-nucleins: A family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci 1998;21: 249-254.
105. Lavedan C: The synuclein family. Genet Res 1998;8:871-880.
106. Maroteaux L, Campanelli JT, Scheller RH: Synuclein: A neuron-specific protein localized to the nucleus and presynapric terminal. J Neurosci 1988;8:2804-2815.
107. Maroteaux L, Scheller RH: The rat brain synucleins: Family of proteins transiently associated with the neuronal membrane. Mol Brain Res 1991;11:335-343.
108. Ueda K, Fukushima H, Masliah E: Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci USA 1993;90: 11282-11286.
109. George J, Jin H, Woods W: Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 1995;15:361-372.
110. Spillantini MG, Schmidt ML, Lee VMY: a-Synuclein in Lewy bodies. Nature 1997;388:839-840.
111. Irizarry M, Growdon J, Gomez-Isla T: Nigral and cortical Lewy bodies and dystrophic nigral neu-rites in Parkinson’s disease and cortical Lewy body disease contain a-synuclein immunoreactivity. J Neuropathol Exp Neurol 1998;57: 334-337.
112. Sunada Y, Saito F, Matsumura K: Differential expression of the parkin gene in the human brain and peripheral leukocytes. Neurosci Lett 1998;254:180-182.
113. Doran JF, Jackson P, Kynoch PAM: Isolation of PGP 9.5, a new human neuron-specific protein detected by high-resolution two-dimensional electrophoresis. J Neu-rochem 1983;40:1542-1547.
114. Day INM, Thompson RJ: Molecular cloning of cDNA coding for human PGP 9.5 protein: A novel cytoplasmic marker for neurons and neuroendocrine cells. FEBS Lett 1987;210:157-160.
115. Lowe J, McDermott H, Landon M: Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases. J Pathol 1990;161:153-160.
116. Day INM, Hinks LJ, Thompson RJ: The structure of the human gene encoding protein gene product 9.5 (PGP 9.5), a neuron specific ubiquitin C-terminal hydrolase. J Biochem 1990;268:521-524.
117. Wilkinson KD, Lee K, Deshpande S: The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. Science 1989; 246:670-673.
118. Larsen CN, Krantz BA, Wilkinson KD: Substrate specificity of deubi-quitinating enzymes: Ubiquitin C-terminal hydrolases. Biochemistry 1998;37:3358-3368.
119. Solano SM, Miller DW, Augood SJ, Young AB, Penney JB Jr: Expression of a-synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain: Genes associated with familial Parkinson’s disease. Ann Neurol 2000;47:201-210.
120. Ebadi M, Srinivasan SK, Baxi MD: Oxidative stress and antioxidant therapy in Parkinson’s disease. Prog Neurobiol 1996;48:1-19.
121. Hao R, Ebadi M, Pfeiffer RF: Selegiline protects dopaminergic neurons in culture from toxic factor(s) present in the cerebrospinal fluid of patients with Parkinson’s disease. Neurosci Lett 1995;200:77-80.
122. Sohal RS, Sohal BH: Hydrogen peroxide release by mitochondria increases during aging. Mech Ageing Dev 1991;57:187-202.
123. Fraga CG, Shigenaga MK, Park JW, Degan P, Ames BN: Oxidative damage to DNA during aging: 8-Hydroxy-2'-deoxyguanosine in rat organ DNA and urine. Proc Natl Acad Sci USA 1991;87:4533-4537.
124. Shigenaga MK, Park JW, Cundy KC, Gimeno CJ, Ames BN: In vivo oxidative DNA damage: Measurement of 8-hydroxy-2'-deoxyguano-sine in DNA and urine by high-performance liquid chromatography with electrochemical detection. Methods Enzymol 1990;6: 521-530.
125. Ames BN, Shigenaga MK, Hagen TM: Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci USA 1993;90: 7915-7922.
126. Hayakawa M, Torii K, Sugiyama S, Tanaka M, Ozawa T. Age-associated accumulation of 8-hydroxy-guanosine in mitochondrial DNA of human diaphragm. Biochem Biophys Res Commun 1991;179: 1023-1029.
127. Wei YH, Pang CY, You BJ, Lee HC: Tandem duplications and large-scale deletions of mitochondrial DNA are early molecular events of human aging process. Ann NY Acad Sci 1996;786:82-101.
128. 10in patients with Parkinson’s disease. J Neural Transm 2000;107:177-181.
129. Gotz ME, Gerstner A, Harth R, Dirr A, Janetsky B, Kuhn W, Rie-derer P, Gerlach M: Altered redox state of platelet coenzyme Q10 in Parkinson’s disease. J Neural Transm 2000;107:41-48.